Roclanda is a prescription ophthalmic solution used to lower elevated intraocular pressure in adults suffering from primary open-angle glaucoma or ocular hypertension. It is specifically formulated for patients whose eye pressure remains insufficiently controlled by single-agent therapies. This fixed-dose combination combines two active ingredients that work through distinct physiological pathways to maximize the drainage of aqueous humor. By effectively reducing internal eye pressure, Roclanda helps prevent progressive damage to the optic nerve and subsequent vision loss. The solution is typically administered as a single daily drop in the evening to ensure consistent efficacy. It provides a specialized alternative for patients who cannot use or do not respond adequately to traditional beta-blocker combinations.

Key Features

• Dual-Action Formula: Combines Latanoprost, a prostaglandin analogue, with Netarsudil, a Rho kinase inhibitor, for superior pressure reduction.
• Enhanced Fluid Drainage: Increases aqueous humor outflow through both the trabecular meshwork and the uveoscleral pathways.
• Once-Daily Dosing: Optimized for evening administration, simplifying the treatment regimen compared to using multiple separate eye drops.
• Episcleral Venous Pressure Reduction: Specifically utilizes Netarsudil to lower the pressure in the veins surrounding the eye, further aiding fluid exit.
• Beta-Blocker Free: Offers a critical treatment option for patients with contraindications like asthma, COPD, or certain cardiovascular conditions.
• Targeted Indication: Indicated specifically as a second-line treatment when initial monotherapy fails to reach target intraocular pressure.